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ANTI-TUMOUR therapy upon experimental animals has long served as a model
for attempts to treat cancer in man. As with few exceptions these agents have
marrow depressant qualities there has always been a serious danger that thera-
peutically effective doses will prove lethal as a consequence of haematopoietic
failure. Within the last 10 years some encouragement has come from the demon-
stration that an injection of viable bone marrow can restore haematopoietic
function (Lorenz, Congdon andUphoff, 1952) whengiven after a dose ofirradiation
sufficient to cause haematopoietic failure but insufficient to damage irreparably
the intestinal epithelium. It has been shown quite clearly that this restoration
is due to repopulation ofthe depleted haematopoietic sites by the injected marrow
(Ford et al., 1956).
Barnes et al. (1956) and Barnes and Loutit (1957) were quick to realise the
use of the finding to extend the doses of irradiation available as therapy against
cancer. Others have adopted a similar approach though using radiomimetic
chemicals. Although in both mice (Barnes and Loutit, 1957) and men (Thomas,
Lochte and Ferrebee, 1959) occasional long remissions have been seen after high
dosage therapy followed by injection of bone marrow, the outstanding feature
ofnearly all these attempts to eradicate cancer is their dismal failure.
This failure is, perhaps, not surprising as Hewitt andWilson (1959) have shown
that the dose of irradiation required completely to kill a population ofleukaemic
cells is far in excess ofthat against which bone marrow is therapeutically effective.
There is no reason to suppose that this finding does not hold for most radio-
mimetic agents and most tumours. This is not, however, the whole story.
Bone marrow therapy after application of a marrow depressant has been of two
principal types: syngeneic and allogeneic.t In the former the treated recipient
and the healthy donor are genetically similar (as mice within an inbred line or as
identical twins) in the latter they are genetically dissimilar (as two individuals
in an outbred population or as mice from two different inbred lines). There are
no adverse consequences of syngeneic marrow therapy but the allogeneic form
usually leads to a wasting syndrome which often ends in death, and which is
probably a consequence of an immunological attack by the donor marTow against
* Present address: Research Institute of Oncopathology, Rith Gyorgy utca 5, Budapest XII,
Hungary.
t Allogeneic marrow therapy after irradiation is only successful because the radiation suppressas
the immune response of the host and there is thus little or no immunological impediment to the
growth of the donor marrow. Not all the chemical agents employed have such a marked effect upon
immune responses and for this reason it has proved difficult to get success with allogeneic marrow
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its genetically foreign host (Uphoff, 1957; Uphoff and Law, 1958). It has been
suggested that in cases where the tumour is of host-type this attack by donor
cells against the host might result in complete destruction of the tumour (Barnes
and Loutit, 1957). Though this may occasionally have been borne out in practice,
the host itself has usually perished not long after the apparent eradication of the
tumour.
In an attempt to get a satisfactory result it was decided to use a transplanted
mouse tumour, the NK/Ly ascites (NK/Ly) (N6meth and Kellner, 1960), which
has proved particularly sensitive to irradiation, and to various chemotherapeutic
agents (Nemeth and Kellner, 1961). It was considered that, ifthis tumour could
be made to regress (though not cured) by the use of conventional therapeutic
schedules, a cure might be achieved by using high dosage therapy followed, in
the first instance, by syngeneic bone marrow. To this end either Degranol
(1,6-Di-,8-chloroethylamino-l,6-dideoxymannitol) or X-irradiation was adminis-
tered to CBA female mice carrying the NK/Ly. The effect of an injection of
syngeneic bone marrow upon their survival was studied.
MATERIALS AND METHODS
Mice.-Female mice of the CBA strain which has been inbred in the Chester
Beatty Research Institute for many generations were used throughout. Their
choice was simply on the ground of availability. They weighed 20-25 g. when
used.
Irradiation.-Mice were irradiated by means of a 220 kv Westinghouse X-ray
machine. The beam was not filtered.
TABLE I.-The Survival of CBA Mice After Various Doses of Irradiation or
Degranol, With or Without Syngeneic Bone Marrow Therapy
Bone marrow Number Per cent
Treatment therapy of mice survival Principal cause(s) of death
160 mg./kg. Degranol . None . 30 . 0 . Intestinal damage.
120 ,, , . None 10 0 . . .
100 , ,,. None . 10 0 . Intestinal damage and haema-
topoietic failure.
80 ,, . None . 20 . 15 . Haematopoietic failure.
160 . Yes . 40 . 0 . Intestinal damage.
100 Yes . 40 7
80 Yes . 25 . 68 . Hydrothorax and liver damage.
750r X-rays . . None . 30 . 0 . Haematopoietic failure.
1150r , . . Yes . 30 10 . Intestinal damage.
1050r . Yes . 30 . 30 . ..
950r . . Yes . 30 80 . Intestinal damage and haema-
topoietic failure.
850r . . Yes . 30 . 95
Tumour.-The tumour was maintained in an ascitic form, being passaged
about every second week. For experimental purposes the ascitic fluid was taken
ten days after implantation and after appropriate dilution with isotonic saline
was injected intravenously into recipient mice, each receiving approximately
3 x 106 nucleated cells. In a few animals the tumour was maintained as a solid
subcutaneous implant.
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Bone marrow.-Where bone marrow was given after Degranol or irradiation
it was removed from the femurs of CBA female donors, suspended in isotonic
saline, and injected intravenously into the treated host mice. Four femur
equivalents of bone marrow were injected into five mice. This corresponds to a
dose per mouse of 10-12 x 106 nucleated cells. Bone marrow was injected within
6 hours of irradiation and between 6 to 24 hours after treatment with Degranol.
It was assumed on chemical grounds that no Degranol would be available for
reaction with the donor cells 6 hours after its injection.
Experiments.-A few preliminary experiments were necessary to determine
the correct dosage of both Degranol and irradiation, the results of which are
summarised in Table I.
It can be seen that syngeneic bone marrow is effective therapy after 850 r
X-rays and moderately effective after 80 mg./kg. Degranol. It seems that the
Degranol had some toxic effects against which bone marrow was of no avail.
On the grounds ofprevious experience with this and other tumours it was decided
to treat mice 5 days after injection with tumour. It was known that after intra-
venous injection the NK/Ly is rarely obvious as a visible growth until at least
20 days later. Usually at this time lymph nodes, particularly in the region of
the head and neck, become visibly swollen and this is followed later by enlarge-
ment of the thymus and eventually by growths in almost every part of the body.
Most but not all mice are killed within 70 days of their implantation with the
tumour. As will be seen the tumour is not invariably lethal. The results of
the first experiments are illustrated in Fig. 1.
The salient feature of this experiment was that the treated animals died
before the controls. Post mortem examinations were carried out and in every
case the bone marrow appeared to be ofnormal cellularity. Nearly all the treated
animals showed signs ofthe tumour at death and many ofthem died of asphyxia-
tion due to enlargement of the thymus. One remarkable finding was that the
lymphnodes in some ifnot all ofthe treated animals were atrophic even 20or more
days after treatment. Atrophy at this time is not normally observed in syngeneic
bone marrow chimaeras. From this first experiment it was obvious that neither
radiation nor Degranol was sufficient to kill the tumour at the doses used. It
was less obvious but possible that the tumour and its host were in immuno-
logical conflict. In the light of these results two further experiments were
planned.
1. It was intended to give either irradiation or Degranol followed by syngeneic
bone marrow and, 9 days later, at a time when recolonization ofthe bone marrow
is usually complete, Degranol to the irradiated mice and irradiation to the
Degranol-treated mice, again followed by bone marrow. In this way it was
hoped to kill more tumour cells than by one treatment. The treatments were
to bereversedbecause theanimalswerenotlikelyto toleratetwo dosesofDegranol.
The first treatments were given to tumour-bearing mice but 9 days later their
general condition was poor and it was thought unlikely that they would survive
a second treatment. Blood counts revealed a severe anaemia and it was decided
to give the animals an injection of syngeneic spleen cells. It was expected that
this measure might remedy the apparent haematopoietic deficiency and, as the
spleen contains a high proportion of lymphoid cells, might also check the growth
of the tumour. The animals died at the same time as had animals given a single
injection of bone marrow (Fig. 1), and the post mortem findings were similar.
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2. Ifthe host animals hadhad anyimmunological reaction against the tumours
then the use of putatively immune animals as donors might have been helpful.
A group of prospective donors were given a large subcutaneous implant of a
solid form of the NK/Ly. One week later their bone marrow was injected intra-
venously to tumour bearing mice after either irradiation or Degranol. The
spleen and axillary and inguinal lymph nodes of the bone marrow donors were
removed, teased out in saline, and injected intraperitoneally into the bone marrow
recipients, each of which received a total of circa 100 x 106 cells. It was hoped
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FIa. 1.-The survival of CBA female mice after
(a) NK/Ly ascites on day 0.
(b) NK/Ly ascites on day -5, 80 mg./kg. Degranol, i.v., on day 0.
(c) NK/Ly ascites on day -5, 80 mg./kg. Degranol, i.v., followed by 12 x 106 cells
sylngeneic bone marrow, i.v., on day 0.
(d) As (c) but with 850 r instead of Degranol.
(e) NK/Ly ascites on day -5, 80 mg./kg. Degranol, i.v., followed by 12 x 106 cells,
syngeneic bone marrow, i.v., on day 0, 50 x 106 cells syngeneic spleen, i.v., on day 9.
(f) As (e) but with 850 r instead of Degranol.
At least 30 mice in each group.
that in these circumstances the hypothetical balance between growth of the
tumour and the immune response ofthe host would be tipped in favourofthe host.
Infactall thetreatedanimalsdiedwithin 14days (Fig. 2). Theyallshowedhaema-
topoietic aplasia. The tumour was not apparent but then it rarely is before 20
days after intravenous injection.
One further experiment was carried out. Two groups of CBA mice were
injected intravenously with 3 x 106 cells of NK/Ly ascites per mouse. The
haematocrits and haemoglobin levels of one group were determined after various
time intervals (Fig. 3). The other group, 5 days after injection of the tumours,
were given 850 r followed shortly by 10 x 106 cells of CBA bone marrow and
their blood pictures were followed as before (Fig. 3). It was apparent that the
presence of tumours induced a transient but considerable anaemia and that the
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Fic. 2.-The survival of CBA mice after:
(a) NK/Ly ascites on day 0.
(b) NK/Ly ascites on day -5, 80 mg./kg. Degranol, i.p., followed by 6 x 106 cells of syn-
geneic bone marrow, i.v., +100 x 106 cells syngeneic spleen and lymph nodes, i.p., all from
mice bearing a 7 day old subcutaneous implant of the NK lymphoma.
(c) As (b) but with 850 r instead of Degranol.
At least 30 mice in each group.
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FIG. 3.-The haematocrits (PCV) and haemoglobin (Hb) levels ofCBA female mice after intra-
venous injection of 3 x 106 cells of NK/Ly ascites.
---O--- PCV Tumour alone.
Hb
- * PCV Tumour on day 0, 850r, total body followed by 10 x 106 cells
- RHb f syngeneic bone marrow on day 5.
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effect of irradiation plus bone marrow injection was to intensify and prolong
the anaemia. High mortality in the second group of mice, attributable to un-
controlled haemorrhage, limited the number bled to give the results indicated in
the later part of the graph. Otherwise each point represents a mean from at
least four mice, no mouse being bled more than once every 8 days.
DISCUSSION
One interpretation of the experiments recorded depends on an investigation
of the anaemia observed in tumour-bearing mice, with or without irradiation,
in the last experiments. Such a study has been made (Davies, Cross and Lapis,
1962) revealing that a virus or virus-like entity associated with the tumour was
the cause ofthe anaemia. It was shown that all cellular components ofthe blood
were to some extent affected by the supposed virus and that the control of viral
activity was apparently dependent on the immunological responsiveness of the
infected host. Much remains to be clarified about the exact relationship between
the tumour and the virus but sufficient is known to put forward a tentative
explanation of the experimental results here obtained.
The first point is that as the virus tends to suppress, albeit temporarily, the
lymphocyte count of tumour-bearing mice this in itself may facilitate the growth
of the tumour and might perhaps explain the lack of strain specificity of the
tumour. Irradiation, though destroying some tumour cells, would further
deplete the lymphocyte count and the net effect might be accelerated growth of
the tumour. The injection of bone marrow cells could not in the time available
sufficiently increase the amount oflymphoid tissue available to modify this effect
(see Koller, Davies and Doak, 1962, for a detailed consideration of the immuno-
logical consequences of injecting bone marrow after irradiation). The recovery
of haemoglobin and haematocrit values by the 23rd day in irradiated tumour-
bearing mice (Fig. 3) does, however, indicate that some degree of immunological
control over viral activity is finally achieved. The deaths of irradiated tumour-
bearing mice which had been given bone marrow and massive doses of spleen
and lymph node cells from " immune " tumour bearing mice were probably due
to the large numbers of virus particles likely to have been present in the donor
inoculum.
Though it is not yet known to what extent viral multiplication takes place
in the tumour cells it is possible that the sensitivity of the tumour to various
chemotherapeutic agents (N6meth and Kellner, 1961) is to some extent associated
with viral destruction of the tumour; the chemotherapeutic agents then serving
slightly to depress the immune response and permit increased viral activity.*
It would be necessary to assume in this case that any immunological activity of
the host against its tumour is not so depressed as to accelerate growth ofresidual
tumour cells as apparently has happened in the present series of experiments.
It is also possible that damage to infected tumour cells by the chemotherapeutic
agent might itself encourage viral growth (Lapis and Mercer, 1962); a quasi-
induction phenomenon. Such speculation could well form the basis of further
studies.
* It should, however, be emphasised that no evidence ofviral activity has so far been discovered in
those mice which have been used for the screening of chemotherapeutic agents against the NK/Ly
ascites.
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SUMMARY
An account is presented of unsuccessful attempts to cure the NK/Ly ascites
tumour in mice by doses of Degranol or irradiation which, had they not been
followed by syngeneic marrow therapy, would have proved lethal as a consequence
of haematopoietic failure. Reasons for the lack of success are discussed and it is
concluded firstly that even the high doses of anti-tumour agents given were
inisufficient to eradicate the tumour and, secondly, that the treated animals died
before the controls because a virus or virus-like entity associated with the tumour
seriously impeded haematopoietic recovery.
The authors are indebted to Professor P. C. Koller of the Chester Beatty
Research Institute for his guidance throughout this work.
The senior author was supported financially by a Gordon Jacob Fellowship
of the Royal Marsden Hospital for which he is very grateful and in other respects
the work was supported by grants to the Chester Beatty Research Institute
(Institute ofCancer Research: Royal Cancer Hospital) from the Medical Research
Council, the British Empire Cancer Campaign, the Anna Fuller Fund, and the
National Cancer Institute of the National Institutes of Health, U.S. Public
Health Service.
REFERENCES
BARNES, D. W. H., CORP, M. J., LoUTIT, J. F. AND NEAL, F. E.-(1956) Brit. med. J.,
ii, 626.
Idem AND LOUTIT, J. F. (1957) Brit. J. Haematol., 3, 241.
DAVIES, A. J. S., CROSS, A. M. AND LAPIS, K.-(1962) Brit. J. Cancer, 16, 770.
FORD, C. E., HAMERTON, J. L., BARNES, D. W. H. AND LOUTIT, J. F.-(1956) Nature,
Lond.. 177, 452.
HEWITT, H. B. AND WILSON, C. W.-(1959) Brit. J. Cancer, 13, 69.
KOLLER, P. C., DAVIES, A. J. S. AND DOAK, S. M. A.-(1962) 'Advances in Cancer Re-
search', New York (Academic Press), p. 181.
LAPIS, K. AND MERCER, E. H. (1962) Cancer Res., in press.
LORENZ, E., CONGDON, C. C. AND UPHOFF, D.-(1952) Radiology, 58, 863.
NEMETH, L. AND KELLNER, B.-(1960) Naturwissenschaften, 47, 544.-(1961) Neoplasma,
8, 337.
THOMAS, E. D., LoCHTE, H. L. AND FERREBEE, J. W.-(1959) Blood, 14, 1.
UPHOFF, D. E.-(1957) J. nat. Cancer Inst., 20, 123.
Idem AND LAW, L. W.-(1958) Ibid., 20, 617.
32